Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Biosimilars market currently led by Sandoz and Teva

Industry Sector

Healthcare and Medical

Published

28 November 2012

Author

Mike King

Type of News

Market

The global biosimilar market has been forecast to increase at a compound annual growth rate (CAGR) of 36.6% over 2009-2018, increasing from a valuation of US$2 billion in 2012, to hit a market value of US$19.4 billion by 2018.

This growth can be attributed to some of the top-selling biologics coming off-patent over the coming few years and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity.

Patent expiries of major biotechnology drugs constitute one of the key growth drivers for the biosimilars market. Several major biotech drugs such as Roche's Herceptin and Rituxan, Sanofi's Lantus, Amgen's Neulasta are expected to lose patents, starting from the year 2012.

This would translate into tremendous opportunities for biosimilar manufacturers in the coming years. Biosimilar manufacturers would also receive a boost for continuing efforts to curtail healthcare costs worldwide, as they show potential to offer cost savings to insurance companies, government organisations, and patients alike.

Biosimilars are an exciting opportunity for companies seeking to enter or maintain a presence in the biopharmaceutical industry.

The biosimilars market is highly fragmented and dominated by major market players such as Biocon, Dr. Reddy's Laboratories, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

Sandoz and Teva are the major players in developed markets currently, although their position will be challenged in the near future by many other generics and Big Pharma companies. Merck & Co.'s potential $720 million deal with Hanwha Chemical shows the level of money companies are willing to invest in this fast-growing market.

Current leaders, in order to maintain market share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants.

For more information on the biosimilars market, see the latest research: Biosimilars Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings